Christopher Barry - NuVasive CEO, Director
| NUVADelisted Stock | USD 42.35 0.85 1.97% |
CEO
Mr. J. Christopher Barry was appointed Chief Executive Officer, Director of the Company effective November 5, 2018. Prior to joining NuVasive, Mr. Barry served as Senior Vice President and President of Surgical Innovations for Medtronic plc, a global medical technology company, from January 2015 to October 2018. Mr. Barry joined Medtronic following its January 2015 acquisition of Covidien plc, a global healthcare technology and medical supplies provider. Mr. Barry previously spent 15 years with Covidien in various sales and leadership roles, most recently as President, Advanced Surgical Technologies, from October 2013 to January 2015 since 2018.
| Age | 49 |
| Tenure | 6 years |
| Phone | 858 909 1800 |
| Web | https://www.nuvasive.com |
NuVasive Management Efficiency
The company has return on total asset (ROA) of 0.0242 % which means that it generated a profit of $0.0242 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0331 %, meaning that it created $0.0331 on every $100 dollars invested by stockholders. NuVasive's management efficiency ratios could be used to measure how well NuVasive manages its routine affairs as well as how well it operates its assets and liabilities.NuVasive currently holds 1.01 B in liabilities with Debt to Equity (D/E) ratio of 1.22, which is about average as compared to similar companies. NuVasive has a current ratio of 1.15, suggesting that it may not be capable to disburse its financial obligations when due. Note, when we think about NuVasive's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 12 records | CEO Age | ||
| Michael CPA | Avanos Medical | 51 | |
| Damien McDonald | LivaNova PLC | 59 | |
| Kevin Thornal | Nevro Corp | 50 | |
| Massimo Calafiore | Orthofix Medical | 52 | |
| Joseph Dziedzic | Integer Holdings Corp | 56 | |
| Mark Throdahl | Orthopediatrics Corp | 73 | |
| Vladimir Makatsaria | LivaNova PLC | 51 | |
| Glendon French | Pulmonx Corp | 62 | |
| Steven Williamson | Pulmonx Corp | 51 | |
| Joseph Woody | Avanos Medical | 58 | |
| Burkhard Prause | Bruker | 57 | |
| Albert DaCosta | Paragon 28 | 51 | |
Management Performance
| Return On Equity | 0.0331 | |||
| Return On Asset | 0.0242 |
NuVasive Leadership Team
Elected by the shareholders, the NuVasive's board of directors comprises two types of representatives: NuVasive inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NuVasive. The board's role is to monitor NuVasive's management team and ensure that shareholders' interests are well served. NuVasive's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NuVasive's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Juliet Cunningham, VP Relations | ||
| Sean Freeman, Sr Devel | ||
| Michael Farrington, VP Culture | ||
| Nathaniel Esq, Gen VP | ||
| Dale Wolf, VP Operations | ||
| Ryan Donahoe, VP Officer | ||
| Matthew Harbaugh, Ex CFO | ||
| Johnson Lai, Chief Officer | ||
| Marc Rosenbaum, Co VP | ||
| Christopher Barry, CEO, Director |
NuVasive Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NuVasive a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0331 | |||
| Return On Asset | 0.0242 | |||
| Profit Margin | 0.02 % | |||
| Operating Margin | 0.07 % | |||
| Current Valuation | 2.91 B | |||
| Shares Outstanding | 52.45 M | |||
| Shares Owned By Insiders | 0.27 % | |||
| Shares Owned By Institutions | 99.73 % | |||
| Number Of Shares Shorted | 5.76 M | |||
| Price To Earning | 51.79 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in NuVasive Stock
If you are still planning to invest in NuVasive check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NuVasive's history and understand the potential risks before investing.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |